Indore Online Journal

Graft vs Host Disease Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Cellestia Biotech, Pfizer, Chia Tai Tianqing Pharma, Regimmune

 Breaking News
  • No posts were found

Graft vs Host Disease Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Cellestia Biotech, Pfizer, Chia Tai Tianqing Pharma, Regimmune

April 16
13:00 2024
Graft vs Host Disease Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Cellestia Biotech, Pfizer, Chia Tai Tianqing Pharma, Regimmune
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Graft vs Host Disease pipeline constitutes 60+ key companies continuously working towards developing 65+ Graft vs Host Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Graft vs Host Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Graft vs Host Disease Pipeline Insight, 2024 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Graft vs Host Disease Market.

 

Some of the key takeaways from the Graft vs Host Disease Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Graft vs Host Disease treatment therapies with a considerable amount of success over the years. 
  • Graft vs Host Disease companies working in the treatment market are Cellestia Biotech, Pfizer, Chia Tai Tianqing Pharmaceutical, Regimmune Corporation, Syndax Pharmaceuticals, MaaT Pharma, Medac, Equillium, Xenikos, and others, are developing therapies for the Graft vs Host Disease treatment 
  • Emerging Graft vs Host Disease therapies in the different phases of clinical trials are- CB103, Glasdegib, TQ 05105, RGI-2001, Axatilimab, MaaT013, MC 0518, Itolizumab, T-Guard, and others are expected to have a significant impact on the Graft vs Host Disease market in the coming years.   
  • In June, 2023, A new approach to preventing graft versus host disease (GVHD) for blood cancer patients receiving allogeneic hematopoietic cell transplantation (HCT) from well-matched donors significantly increases GVHD-free/relapse-free survival (GRFS), according to results of a Phase III randomised clinical trial published in the New England Journal of Medicine
  • In June 2023, In a preclinical study led by researchers from Penn Medicine and Dana-Farber/Boston Children’s Cancer and Blood Disorders Centre, an experimental antibody therapy largely prevented the bone marrow transplant complication known as graft versus host disease (GVHD) in the intestines without causing widespread immune suppression
  • In December 2022, Ono Pharmaceutical has the sole opportunity to buy Equillium’s itolizumab rights through a recently disclosed option and asset purchase agreement between the two parties. These rights include the ability to market itolizumab in the US, Canada, Australia, and New Zealand for any therapeutic purposes
  • In October 2022, For the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD), Mesoblast Limited announced that it had submitted to the U.S. Food and Drug Administration (FDA) significant new information on clinical and potency assay items identified in the Complete Response Letter (CRL) it had received from FDA in September 2020
  • In August 2022, Imbruvica from Johnson & Johnson and AbbVie was given FDA approval to treat chronic graft-versus-host disease in children aged 1 to 11. For this age group, it is the first available therapeutic choice. Imbruvica’s use for people with cGVHD aged 12 and older received FDA approval for the first time in 2017
  • In June 2022, A global pivotal Phase III clinical study comparing T-Guard and ruxolitinib for the treatment of patients with Grade III or IV steroid-refractory acute graft-versus-host disease (SR-aGVHD) after allogeneic hematopoietic stem cell transplant (allo-HSCT) has enrolled its first patient, according to Xenikos B.V
  • In April 2022, In order to compare the effectiveness and safety of itolizumab administered intravenously (IV) versus placebo as a first-line therapy in up to 200 adult and adolescent patients with Grade III–IV aGVHD or Grade II aGVHD with less GI involvement, in combination with high doses of corticosteroids—the current standard of care—Ellium has started a Phase III, randomised, double-blind, placebo-controlled multicenter study

 

Graft vs Host Disease Overview

Graft-versus-host disease (GvHD) is an immune disorder that develops when immune cells (T cells) from the donor, also referred to as the graft or graft cells, attack the recipient patient host’s tissues (healthy cells); the condition is a side effect that is frequently experienced after an allogeneic bone marrow transplant (stem cell transplant).

 

Get a Free Sample PDF Report to know more about Graft vs Host Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-pipeline-insight

 

Emerging Graft vs Host Disease Drugs Under Different Phases of Clinical Development Include:

  • CB103: Cellestia Biotech
  • Glasdegib: Pfizer
  • TQ 05105: Chia Tai Tianqing Pharmaceutical
  • RGI-2001: Regimmune Corporation
  • Axatilimab: Syndax Pharmaceuticals
  • MaaT013: MaaT Pharma
  • MC 0518: Medac
  • Itolizumab: Equillium
  • Elranatamab: Pfizer
  • Felzartamab: Janssen Pharmaceutical
  • T-Guard: Xenikos
  • MaaT013: MaaT Pharma
  • Axatilimab: Syndax Pharmaceuticals
  • TQ 05105: Chia Tai Tianqing Pharmaceutical Group

 

Graft vs Host Disease Route of Administration

Graft vs Host Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Intravenous
  • Subcutaneous

 

Graft vs Host Disease Molecule Type

Graft vs Host Disease Products have been categorized under various Molecule types, such as

  • Small molecule
  • Cell Therapy
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy 

 

Graft vs Host Disease Pipeline Therapeutics Assessment

  • Graft vs Host Disease Assessment by Product Type
  • Graft vs Host Disease By Stage and Product Type
  • Graft vs Host Disease Assessment by Route of Administration
  • Graft vs Host Disease By Stage and Route of Administration
  • Graft vs Host Disease Assessment by Molecule Type
  • Graft vs Host Disease by Stage and Molecule Type

 

DelveInsight’s Graft vs Host Disease Report covers around 65+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Graft vs Host Disease product details are provided in the report. Download the Graft vs Host Disease pipeline report to learn more about the emerging Graft vs Host Disease therapies

 

Some of the key companies in the Graft vs Host Disease Therapeutics Market include:

Key companies developing therapies for Graft vs Host Disease are – Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Medsenic, Xenothera, Xenikos, AltruBio Inc., Biogen, OncoImmune, Inc., Cellect Biotechnology,   AstraZeneca, Bristol-Myers Squibb, Dystrogen Therapeutics, CTI BioPharma, Ossium Health, Inc., Orca Biosystems, Inc., Synthetic Biologics Inc., Cellenkos, Corvus Pharmaceuticals, ImStem Biotechnology, Rheos Medicines, Equillium, Cellestia Biotech, Genentech, Humanigen, CSL Behring, ADIENNE, and others.

 

Graft vs Host Disease Pipeline Analysis:

The Graft vs Host Disease pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Graft vs Host Disease with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Graft vs Host Disease Treatment.
  • Graft vs Host Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Graft vs Host Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Graft vs Host Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Graft vs Host Disease drugs and therapies

 

Graft vs Host Disease Pipeline Market Drivers

  • Increase in the number of patients suffering from chronic GvHD, robust Pipeline of GvHD are some of the important factors that are fueling the Graft vs Host Disease Market.

 

Graft vs Host Disease Pipeline Market Barriers

  • However, high cost of treatment, recognizing the limitations of currently available aGVHD therapies and other factors are creating obstacles in the Graft vs Host Disease Market growth.

 

Scope of Graft vs Host Disease Pipeline Drug Insight    

  • Coverage: Global
  • Key Graft vs Host Disease Companies: Cellestia Biotech, Pfizer, Chia Tai Tianqing Pharmaceutical, Regimmune Corporation, Syndax Pharmaceuticals, MaaT Pharma, Medac, Equillium, Xenikos, and others
  • Key Graft vs Host Disease Therapies: CB103, Glasdegib, TQ 05105, RGI-2001, Axatilimab, MaaT013, MC 0518, Itolizumab, T-Guard, and others
  • Graft vs Host Disease Therapeutic Assessment: Graft vs Host Disease current marketed and Graft vs Host Disease emerging therapies
  • Graft vs Host Disease Market Dynamics: Graft vs Host Disease market drivers and Graft vs Host Disease market barriers 

 

Request for Sample PDF Report for Graft vs Host Disease Pipeline Assessment and clinical trials

 

Table of Contents 

1. Graft vs Host Disease Report Introduction

2. Graft vs Host Disease Executive Summary

3. Graft vs Host Disease Overview

4. Graft vs Host Disease- Analytical Perspective In-depth Commercial Assessment

5. Graft vs Host Disease Pipeline Therapeutics

6. Graft vs Host Disease Late Stage Products (Phase II/III)

7. Graft vs Host Disease Mid Stage Products (Phase II)

8. Graft vs Host Disease Early Stage Products (Phase I)

9. Graft vs Host Disease Preclinical Stage Products

10. Graft vs Host Disease Therapeutics Assessment

11. Graft vs Host Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Graft vs Host Disease Key Companies

14. Graft vs Host Disease Key Products

15. Graft vs Host Disease Unmet Needs

16 . Graft vs Host Disease Market Drivers and Barriers

17. Graft vs Host Disease Future Perspectives and Conclusion

18. Graft vs Host Disease Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Categories